Cost and impact of early diagnosis in primary immunodeficiency disease: A literature review
Open Access
- 1 April 2020
- journal article
- review article
- Published by Elsevier in Clinical Immunology
- Vol. 213, 108359
Abstract
No abstract availableKeywords
Funding Information
- ZonMw
This publication has 46 references indexed in Scilit:
- Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiencyTransfusion Medicine, 2012
- A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID)Molecular Genetics and Metabolism, 2011
- Chronic granulomatous disease: Overview and hematopoietic stem cell transplantationJournal of Allergy and Clinical Immunology, 2011
- Relevance of laboratory testing for the diagnosis of primary immunodeficiencies: a review of case-based examples of selected immunodeficienciesClinical and Molecular Allergy, 2011
- Economic evaluation of immunoglobulin replacement in patients with primary antibody deficienciesClinical and Experimental Immunology, 2009
- A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiencyClinical and Experimental Immunology, 2007
- Potential Costs and Benefits of Newborn Screening for Severe Combined ImmunodeficiencyThe Journal of Pediatrics, 2005
- Primary antibody deficiency and diagnostic delay: Table 1Journal of Clinical Pathology, 2005
- Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insuranceThe European Journal of Health Economics, 2005
- Cost utility analysis: What should be measured?Social Science & Medicine, 1994